Applied Filters
How patents for transgenic mice got caught in a sufficiency trap
As the UK Supreme Court reverses a Court of Appeal decision relating to sufficiency, the ruling leaves patent applicants in a potentially difficult position, argues David Fyfield of Charles Russell Speechlys.
EPO’s G3/19: no turning back?
The EPO’s May 2020 decision in G3/19, on the patentability of certain plants, was among the most controversial in the office’s history. Anna Gregson of Mathys & Squire explores the implications.
Analysis: Kymab’s ‘patent bargain’ clarification and why it matters
Yesterday’s UK Supreme Court decision in Kymab v Regeneron is expected to have profound implications for innovative life sciences companies, according to lawyers.
Will Big Pharma get the bug for microbiome therapies?
The exciting field of microbiome therapeutics offers many opportunities for ‘Big Pharma’ players that are staring over the exclusivity cliff, say Craig Thomson, Leena Contarino and Andrew Wells of HGF.
Conference preview: 12th Pharma & Biotech Patent Litigation
Secondary medical use case trends and research exemptions are just two issues set to be discussed at C5’s 12th Pharma & Biotech Patent Litigation meeting, on February 25–26 in Amsterdam.
Event preview: BIO-Europe returns to Hamburg
The special 25th anniversary BIO-Europe 2019 global life science partnering event will be held November 11–13, 2019, in Hamburg, Germany.
M&A: Year of the megadeal
LSIPR’s Sarah Morgan investigates the current state of play of M&A in the sector and predicts the next year of activity.
IP portfolios: the five biggest headaches for in-house counsel
In-house counsel face daily challenges when managing and maintaining their IP portfolios. LSIPR asked two in-house counsel for the biggest challenges they face when managing and maintaining their IP portfolios. Here are the five things we learned.
Secondary patents: Moscow mewl
An intervention by Russia’s IP ombudsman seeks to solve the validity issue over secondary patents, but is it needed, asks Maxim Sobolev of Rouse.
CRISPR: Hearing all about it
There is no doubting the importance of next year’s CRISPR appeal, but any conclusions about the parties’ prior art have consequences for elsewhere too, say Catherine Coombes and Emma Longland of HGF.
